So either they will be able to confirm that first patient has been dosed by then and that info will be part of the presentation or, per IR, the  "complexity of commencing a trial"  (of 100 patients) is such that RVX has no idea when the first patient is going to be dosed and this is all they can think of to stop the share price decline.

I know which option I think is more likely.